


IN THE CLAIMS:

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1 - 21 (Canceled)

22. (New) A method of inhibiting apoptosis in a patient for the treatment of prion diseases which comprises administering an effective amount of a compound of formula (I):



in which:

- R₁ represents a halogen or a CF₃, (C₁-C₄)alkyl or (C₁-C₄)alkoxy group;
- Y represents a nitrogen atom [or a CH group];
- Z' and Z'' each represent hydrogen or a (C₁-C₃) alkyl group, or one represents hydrogen and the other a hydroxy group, or both, together, represent an oxo group;
- Z represents


a phenyl radical;

a phenyl radical monosubstituted with a substituent X, X being

- a) a (C₁-C₆)alkyl; (C₁-C₆)alkoxy; (C₃-C₇)carboxyalkyl; (C₁-C₄)alkoxycarbonyl(C₁-C₆)alkyl; (C₃-C₇)carboxyalkoxy or (C₁-C₄)alkoxycarbonyl(C₁-C₆)alkoxy group;
- b) a group selected from a (C₃-C₇)cycloalkyl, (C₃-C₇)cycloalkyloxy, (C₃-C₇)cycloalkylmethyl, (C₃-C₇)cycloalkylamino and cyclohexenyl group, it being possible for said group to be substituted with a halogen, hydroxy, (C₁-C₄)alkoxy, carboxy, (C₁-C₄)alkoxycarbonyl, amino, mono- or di-(C₁-C₄)alkylamino;

- c) a group selected from a phenyl, phenoxy, phenylamino, N-(C₁-C₃)alkylphenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl or styryl, it being possible for said group to be mono- or poly-substituted on the phenyl group with a halogen, CF₃, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, cyano, amino, mono- or di-(C₁-C₄)alkylamino, (C₁-C₄)acylamino, carboxy, (C₁-C₄)alkoxycarbonyl, aminocarbonyl, mono- or di-(C₁-C₄)alkylaminocarbonyl, amino(C₁-C₄)alkyl, hydroxy(C₁-C₄)alkyl or halo(C₁-C₄)alkyl;
- a phenyl radical disubstituted with a substituent R₂, R₂ being a halogen or a hydroxy, methyl, ethyl, (C₃-C₆)alkyl, (C₁-C₄)alkoxy or trifluoromethyl group and with a substituent X, X being as defined above;
 - a 1-naphthyl or 2-naphthyl radical;
 - a 1-naphthyl or 2-naphthyl radical substituted in positions 5, 6, 7 and/or 8 with one or two hydroxyl groups, one or two (C₁-C₄)alkoxy groups or a 6,7-methylenedioxy group;
 - or Z" is hydrogen and Z and Z' represent, each independently, a non-substituted or mono-, di- or tri-substituted phenyl group;
- or of one of its pharmaceutically acceptable salts and solvates.

Respectfully submitted,


Karen I. Krupen, Reg. No. 34,647
Attorney for Applicant

sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-4658
Telefax: 908-231-2626

Docket No. IVD1000 US DIV 1